Dawnrays Pharmaceutical (Holdings) Dividends and Buybacks
Dividend criteria checks 4/6
Dawnrays Pharmaceutical (Holdings) is a dividend paying company with a current yield of 6.38% that is well covered by earnings.
Key information
6.4%
Dividend yield
-0.03%
Buyback Yield
Total Shareholder Yield | 6.3% |
Future Dividend Yield | n/a |
Dividend Growth | 12.8% |
Next dividend pay date | n/a |
Ex dividend date | n/a |
Dividend per share | HK$0.080 |
Payout ratio | 19% |
Recent dividend and buyback updates
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015
Sep 11Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065
May 25Recent updates
Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Earnings Might Not Be As Promising As They Seem
Sep 21Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015
Sep 11Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.065
May 25Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.065
Apr 22Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.065
Apr 08Dawnrays Pharmaceutical (Holdings) (HKG:2348) Is Due To Pay A Dividend Of CN¥0.065
Mar 25Dawnrays Pharmaceutical (Holdings) (HKG:2348) Has Announced A Dividend Of CN¥0.015
Aug 30Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Shareholders Will Receive A Bigger Dividend Than Last Year
May 26Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of CN¥0.073
Apr 04Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be CN¥0.015
Sep 19Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Solid Profits Have Weak Fundamentals
Sep 22Dawnrays Pharmaceutical (Holdings) (HKG:2348) Will Pay A Dividend Of HK$0.015
Sep 12Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Dividend Will Be HK$0.015
Aug 29Here's How We Evaluate Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Dividend
Feb 28Would Shareholders Who Purchased Dawnrays Pharmaceutical (Holdings)'s (HKG:2348) Stock Five Years Be Happy With The Share price Today?
Feb 07Yung Lai Hung Is The Co-Founder & Executive Director of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) And They Just Picked Up 34% More Shares
Jan 14Dawnrays Pharmaceutical (Holdings) Limited's (HKG:2348) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Dec 22What Kind Of Investors Own Most Of Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348)?
Dec 09Three Things You Should Check Before Buying Dawnrays Pharmaceutical (Holdings) Limited (HKG:2348) For Its Dividend
Nov 23Stability and Growth of Payments
Fetching dividends data
Stable Dividend: 2348's dividend payments have been volatile in the past 10 years.
Growing Dividend: 2348's dividend payments have increased over the past 10 years.
Dividend Yield vs Market
Dawnrays Pharmaceutical (Holdings) Dividend Yield vs Market |
---|
Segment | Dividend Yield |
---|---|
Company (2348) | 6.4% |
Market Bottom 25% (HK) | 3.2% |
Market Top 25% (HK) | 8.0% |
Industry Average (Pharmaceuticals) | 3.9% |
Analyst forecast (2348) (up to 3 years) | n/a |
Notable Dividend: 2348's dividend (6.38%) is higher than the bottom 25% of dividend payers in the Hong Kong market (3.25%).
High Dividend: 2348's dividend (6.38%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.98%).
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (19.4%), 2348's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: At its current cash payout ratio (86.4%), 2348's dividend payments are covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/06 09:42 |
End of Day Share Price | 2025/01/06 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dawnrays Pharmaceutical (Holdings) Limited is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
John Mulcahy | AMC Wanhai Securities Ltd. |
Wing-Tai Ng | China Galaxy International Securities (Hong Kong) |
Wai Chak Yuen | Cinda International Research Limited |